Literature DB >> 6226197

Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy.

M L Marcus, S Koyanagi, D G Harrison, D B Doty, L F Hiratzka, C L Eastham.   

Abstract

Myocardial ischemia is frequently observed in patients with cardiac hypertrophy even when the conduit coronary arteries are normal. Recent studies indicate that impaired coronary reserve in hypertrophied hearts probably occurs because growth of the coronary bed does not keep pace with increases in cardiac mass. The imbalance between vascular proliferation and muscle growth is probably most severe when cardiac hypertrophy is produced by pressure overload. Experimental studies also suggest that abnormalities intrinsic to pressure-hypertrophied heart muscle (decreased capillary density; decreased coronary reserve; electrophysiologic abnormalities) adversely affect the response of the enlarged heart to sudden coronary occlusion. When animals with hypertension and left ventricular hypertrophy are subjected to sudden coronary occlusion, the incidence of sudden cardiac death is increased severalfold and infarct size is substantially augmented. These observations suggest that abnormalities in the coronary microcirculation that accompany cardiac hypertrophy play a significant role in the pathogenesis of the complications associated with cardiac hypertrophy.

Entities:  

Mesh:

Year:  1983        PMID: 6226197     DOI: 10.1016/0002-9343(83)90120-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

1.  Estimation of coronary flow reserve: can SPECT compete with other modalities?

Authors:  G T Gullberg; E V Di Bella; A J Sinusas
Journal:  J Nucl Cardiol       Date:  2001 Sep-Oct       Impact factor: 5.952

Review 2.  Myocardial perfusion and coronary microcirculation: from pathophysiology to clinical application.

Authors:  Antonio L'Abbate; Gianmario Sambuceti; Danilo Neglia
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

3.  Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 1: Cardiovascular progenitor cells, their functions and sources.

Authors:  C Qian; R G Schoemaker; W H van Gilst; B Yu; A J M Roks
Journal:  Neth Heart J       Date:  2008-09       Impact factor: 2.380

Review 4.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Ca(2+) channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats.

Authors:  Takao Nishizawa; Xian Wu Cheng; Zhehu Jin; Koji Obata; Kohzo Nagata; Akihiro Hirashiki; Takeshi Sasaki; Akiko Noda; Kyosuke Takeshita; Hideo Izawa; Guo-Ping Shi; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

Review 6.  Imaging in hypertensive heart disease.

Authors:  Rajesh Janardhanan; Christopher M Kramer
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-02

7.  Regional oxygen supply and consumption balance in experimental left ventricular hypertrophy.

Authors:  P M Scholz; G J Grover; J W Mackenzie; H R Weiss
Journal:  Basic Res Cardiol       Date:  1990 Nov-Dec       Impact factor: 17.165

8.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

Review 9.  Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2016-05-16       Impact factor: 4.132

10.  Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure.

Authors:  Taimoor Hashim; Shereen Elbaz; Kanan Patel; Charity J Morgan; Gregg C Fonarow; Jerome L Fleg; Gerald McGwin; Gary R Cutter; Richard M Allman; Sumanth D Prabhu; Michael R Zile; Robert C Bourge; Ali Ahmed
Journal:  Am J Med       Date:  2013-09-23       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.